AnaptysBio, Inc. (ANAB) vs ArriVent BioPharma, Inc. (AVBP)

A side-by-side comparison of AnaptysBio, Inc. and ArriVent BioPharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
AnaptysBio, Inc. logo
ANAB
AnaptysBio, Inc.
$1.42B
$47.89HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ArriVent BioPharma, Inc. logo
AVBP
ArriVent BioPharma, Inc.
$703M
$15.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ANAB vs AVBP

growth of $100 · dividends reinvested · last 3y
ANAB +212.6% (+46.2%/yr)AVBP +42.3% (+12.5%/yr)ANAB compounded faster over this window
100200300400Start $10020252026$313$142
ANAB AVBP

ANAB vs AVBP: by the numbers

  • •ANAB is the larger company ($1.42B vs $703M market cap).
  • •ANAB is profitable (82.37% net margin) while AVBP runs a net loss (0.00%).

Metrics side by side

Valuation

MetricANABAVBP
P/E ratio8.92N/A
P/S ratio5.97N/A
P/B ratio133.961.92
EV / EBITDA11.44N/A
FCF yield1.27%N/A

Profitability

MetricANABAVBP
Gross margin98.97%0.00%
Operating margin20.42%0.00%
Net margin82.37%0.00%
ROE1849.06%-44.63%
ROIC47.55%-47.96%

Growth (annualized)

MetricANABAVBP
Revenue CAGR (5Y)18.60%N/A
FCF CAGR (5Y)27.41%N/A
Total return CAGR (5Y)21.54%N/A

Frequently asked

Is ANAB or AVBP more profitable?
ANAB runs the higher net margin — ANAB at 82.37% versus AVBP at 0.00%.

Go deeper

Full ANAB analysisFull AVBP analysisInteractive comparison tool

Dig into the metrics

AnaptysBio P/E ratioAnaptysBio ROEArriVent BioPharma ROEAnaptysBio operating marginArriVent BioPharma operating marginAnaptysBio revenue growthArriVent BioPharma revenue growthAnaptysBio free cash flowArriVent BioPharma free cash flow

AnaptysBio & ArriVent BioPharma appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.